Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) Overview | 6 | 1 |
| Therapeutics Development | 7 | 4 |
| Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) Products under Development by Stage of Development | 7 | 1 |
| Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) Products under Development by Therapy Area | 8 | 1 |
| Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) Products under Development by Indication | 9 | 2 |
| Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) Products under Development by Companies | 13 | 4 |
| Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) Therapeutics Assessment | 17 | 6 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 2 |
| Assessment by Route of Administration | 20 | 2 |
| Assessment by Molecule Type | 22 | 1 |
| Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) Companies Involved in Therapeutics Development | 23 | 5 |
| AB Science SA | 23 | 2 |
| Boehringer Ingelheim GmbH | 25 | 1 |
| Deciphera Pharmaceuticals, LLC | 26 | 1 |
| Pfizer Inc. | 27 | 1 |
| Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) Drug Profiles | 28 | 32 |
| bosutinib Drug Profile | 28 | 5 |
| masitinib Drug Profile | 33 | 13 |
| nintedanib Drug Profile | 46 | 10 |
| rebastinib tosylate Drug Profile | 56 | 2 |
| tolimidone Drug Profile | 58 | 2 |
| Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) Dormant Projects | 60 | 2 |
| Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) Discontinued Products | 62 | 1 |
| Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2) Featured News &Press Releases | 63 | 18 |
| Jul 11, 2016: AB Science Announces The Publication In The Journal Of Neuroinflammation Of Preclinical Data Showing Neuroprotective Effect Of Masitinib In Amyotrophic Lateral Sclerosis | 63 | 1 |
| Jul 11, 2016: FDA approves first compassionate use of masitinib in amyotrophic lateral sclerosis | 64 | 1 |
| Jul 07, 2016: NICE approves first drug from old Cancer Drugs Fund | 64 | 1 |
| Jul 04, 2016: Review of the conditional marketing authorization application of masitinib in amyotrophic lateral sclerosis (ALS) will follow the standard timeline of the European Medicines Agency (EMA) | 65 | 1 |
| Jun 30, 2016: INMARK now enrolling: first study to evaluate the effect of OFEV (nintedanib) on biomarkers reflecting the underlying fibrotic process in IPF patients | 66 | 1 |
| Jun 27, 2016: New analysis of INPULSIS trials demonstrates efficacy of OFEV (nintedanib) across a range of IPF patients using broader diagnostic criteria | 67 | 1 |
| Jun 13, 2016: Melior Pharmaceuticals Announces Positive Phase 2A Results in Type 2 Diabetes Study | 68 | 1 |
| Jun 06, 2016: AB Science announces that Rapporteurs appointed by the EMA have recommended the filing of masitinib in ALS for conditional marketing authorization | 69 | 1 |
| May 30, 2016: AB Science will Present Phase 3 Data in Severe Systemic Mastocytosis at the International 21St Congress of the European Hematology Association | 70 | 1 |
| May 16, 2016: New Presentations at ATS 2016 Reinforce OFEV (nintedanib) Efficacy, Safety and Tolerability Across Range of Patients with idiopathic pulmonary fibrosis | 71 | 2 |
| May 09, 2016: LUME-Meso trial enrols first patient: Boehringer Ingelheim s new pivotal study investigating nintedanib for the treatment of malignant pleural mesothelioma | 73 | 1 |
| May 02, 2016: AB Science has submitted to EMA the marketing authorization application for Masitinib in the Treatment of Severe Systemic Mastocytosis | 74 | 1 |
| Apr 11, 2016: Masitinib in Amyotrophic Lateral Sclerosis (ALS) | 74 | 4 |
| Apr 06, 2016: AB Science Will Host Live Webcast On Phase 3 Interim Analysis In ALS On 8 April 2016, | 78 | 1 |
| Apr 04, 2016: Ab Science Announces Positive Interim Results From Phase 3 Trial Of Masitinib In Amyotrophic Lateral Sclerosis | 79 | 2 |
| Appendix | 81 | 2 |
| Methodology | 81 | 1 |
| Coverage | 81 | 1 |
| Secondary Research | 81 | 1 |
| Primary Research | 81 | 1 |
| Expert Panel Validation | 81 | 1 |
| Contact Us | 81 | 1 |
| Disclaimer | 82 | 1 |